Andere talen Quest Diagnostics Incorporated

Aandelen

DGX

US74834L1008

Beurs gesloten - Nyse Andere beurzen 22:00:02 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
135,4 ^USD	-1,55%		+7,55%	-1,78%

25/04	Labcorp verslaat kwartaalramingen door sterke vraag naar tests	RE
24/04	QUEST DIAGNOSTICS INCORPORATED : Jefferies & Co. handhaaft koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Fitch Affirms Quest Diagnostics at 'BBB'; Outlook Remains Positive	12:13
Labcorp beats quarterly estimates on strong testing demand	25/04
Quest Diagnostics Reports First Quarter 2024 Financial Results, Raises Guidance for Full Year 2024	24/04
Quest Diagnostics Incorporated : First Quarter 2024 View Transcript of Company Prepared Comments	23/04
Sector Update: Health Care Stocks Steady Pre-Bell Tuesday	23/04
Quest Diagnostics Posts Flat Q1 Adjusted Earnings, Revenue Rises; 2024 Earnings, Revenue Guidance Raised	23/04
Earnings Flash (DGX) QUEST DIAGNOSTICS Reports Q1 Revenue $2.37B, vs. Street Est of $2.29B	23/04
Earnings Flash (DGX) QUEST DIAGNOSTICS Posts Q1 EPS $2.04, vs. Street Est of $1.86	23/04
Quest Diagnostics: Q1 Earnings Snapshot	23/04
Quest Diagnostics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	23/04
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance for Full Year 2024	23/04
Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024	23/04
MORNING BID AMERICAS-Tanking Tesla reports, Europe business beats	23/04
Quest Diagnostics Launches New Test to Help Assess Alzheimer's Disease Risk	22/04
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease	22/04
Quest Diagnostics Adds p-tau217 Blood Biomarker Testing to Suite of Services Designed to Assess Risk and Help Aid Diagnosis of Alzheimer's Disease	22/04
John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission	11/04
Quest Diagnostics Receives Shareholder Proposal from John Chevedden	05/04
Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay	03/04
Quest Collaborating With Broad Clinical Labs to Assess Whole Genome Sequencing Test for Developmental Delay Disorders	02/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Quest Diagnostics Incorporated

Aandelen

DGX

US74834L1008

Andere talen

Filters